Abstract
Pegylated IFN-α2a has been reported in two case reports as being efficacious in treating CDA-I patients. This study aims to assess its efficacy on a series of CDA-I patients. Study sample consisted of seven CDA type 1 transfusion-dependent patients. They received pegylated interferon alpha-2a at an initial dose of 90-180µg once a week, tapered according to clinical response and side effects. Good response was defined as Hb≥10g/dL for ≥3months, partial response was defined as 7≤Hb<10g/dL for ≥3months, and no response was defined as HB<7g/dL for over 3months on treatment. Time to response was defined as the time needed to achieve hemoglobin levels≥10g/dL without transfusion. Patients were evaluated periodically by abdominal ultrasounds to rule out liver adenomas. Five patients (71%) had a good response to treatment. One patient stopped treatment due to side effects. One patient had partial response. One patient, with more severe phenotype and poor compliance, had poor response to treatment. No abnormal findings were found in ultrasound examination. No effect on serum ferritin level could be established. Pegylated interferon α2a therapy is efficacious in CDA-I patients with a reasonable safety profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
